<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82899">
  <stage>Registered</stage>
  <submitdate>12/06/2008</submitdate>
  <approvaldate>20/06/2008</approvaldate>
  <actrnumber>ACTRN12608000304336</actrnumber>
  <trial_identification>
    <studytitle>Dexmedetomidine Sedation for Awake Fibreoptic Bronchoscopy</studytitle>
    <scientifictitle>Feasibility and Safety of Dexmedetomidine Sedation for Patients presenting for Awake Fibreoptic Bronchoscopy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Safety and Feasibility of Dexmedetomidine Sedation for Awake Fibreoptic Bronchoscopy</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Dexmedetomidine sedation as an intravenous infusion to obtain sedation. Initial bolus of 0.5mcg/kg over 10 minutes followed by an infusion of 0.2-0.7mcg/kg/h, titrating to a Ramsay Sedation Score of 4 during the procedure. This infusion would be ceased once bronchoscopy is completed. The estimated time for the bronchoscopy would be about 15-20 minutes.</interventions>
    <comparator>No Control</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Hemodynamic changes from baseline
(observational), Heart rate, Non-invasive blood pressure - systolic, mean and diastolic blood pressure</outcome>
      <timepoint>Baseline, during the sedation and 30 minutes after sedation ceasing (or return to baseline hemodynamics)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Ramsay Sedation Score</outcome>
      <timepoint>Baseline, during the sedation and 30 mins after ceasing sedation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse events monitoring
Bradycardia (Heart rate (HR) &lt;40), Hypotension (Mean Arterial Pressure (MAP)&lt;55mmHg), Nausea</outcome>
      <timepoint>During the sedation and 30 mins after ceasing sedation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient Satisfaction (interview, visual analogue scale)</outcome>
      <timepoint>1 hour post procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proceduralist Satisfaction (visual analogue scale)</outcome>
      <timepoint>Immediately after the procedure</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>18 years and above, Presenting for awake fibreoptic bronchoscopy, and
Not pregnant at the start of the procedure/sedation</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Allergy to dexmedetomidine,2nd degree heart block and above,Hypovolaemia,Hypotensive at the start of the procedure/sedation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>28/07/2008</anticipatedstartdate>
    <actualstartdate>15/12/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate>2/03/2009</actualenddate>
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Keat Lee</primarysponsorname>
    <primarysponsoraddress>Department of Anaesthesia and Pain Management
Royal Melbourne Hospital
Grattan Street
Parkville 3050
VIC</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Royal Melbourne Hospital</fundingname>
      <fundingaddress>Grattan Street
Parkville 3050
VIC</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Ruari Orme</sponsorname>
      <sponsoraddress>Department of Anaesthesia and Pain Management
Royal Melbourne Hospital
Grattan Street
Parkville 3050
VIC</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>We aim to trial dexmedetomidine as a sedating agent for awake diagnostic fibreoptic bronchoscopy. It has a number of unique properties which we feel would be useful - sedating, reduces discomfort and stress during potentially uncomfortable procedures. We would be monitoring for any problems or adverse events during this trial.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Melbourne Health - Human Research Ethics Committee</ethicname>
      <ethicaddress>Royal Melbourne Hospital
Parkville
VIC 3050</ethicaddress>
      <ethicapprovaldate>23/10/2008</ethicapprovaldate>
      <hrec>2008.134</hrec>
      <ethicsubmitdate>2/07/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Keat Lee</name>
      <address>Department of Anaesthesia and Pain Management
Royal Melbourne Hospital
Grattan Street 3050
Parkville
VIC</address>
      <phone>03-93427540</phone>
      <fax />
      <email>keat.lee@mh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Reny Segal</name>
      <address>Department of Anaesthesia and Pain Management
Royal Melbourne Hospital
Grattan Street
Parkville 3050
VIC</address>
      <phone>03-93427540</phone>
      <fax />
      <email>reny.segal@mh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Keat Lee</name>
      <address>Department of Anaesthesia and Pain Management
Royal Melbourne Hospital
Grattan Street 3050
Parkville
VIC</address>
      <phone>03-93427540</phone>
      <fax />
      <email>keat.lee@mh.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Keat Lee</name>
      <address>Department of Anaesthesia and Pain Management
Royal Melbourne Hospital
Grattan Street
Parkville VIC 3050</address>
      <phone>+61393427540</phone>
      <fax />
      <email>Keat.Lee@mh.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>